Navigation Links
Main Street Capital Announces New Portfolio Investment
Date:9/14/2011

HOUSTON, Sept. 14, 2011 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") announced today that it has completed a new lower middle market portfolio investment totaling approximately $6.8 million in invested capital.

The investment was made to support the acquisition of the assets and business of a dedicated investigative facility (the "Company"), which conducts clinical trials for the pharmaceutical industry, by a group of private investors. Main Street's investment consists of $6.3 million in first lien secured debt and a $0.5 million direct equity investment.

Staffed by physicians and support personnel, the Company recruits and treats patients with later stage drugs in development by its pharmaceutical company clients. The Company's primary focus is on Phase II and Phase III metabolic disease trials, principally in diabetes, hypertension and obesity. The Company is headquartered in California.

ABOUT MAIN STREET CAPITAL CORPORATION

Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies. Main Street's lower middle market investments are made to support management buyouts, recapitalizations, growth financings and acquisitions of companies that operate in diverse industry sectors and generally have annual revenues ranging from $10 million to $100 million.  Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides "one stop" financing alternatives within its lower middle market portfolio. Main Street also maintains a portfolio of privately placed, interest-bearing debt investments in middle market businesses that are generally larger in size than its lower middle market portfolio companies.

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, Chief Financial Officer and Senior Managing Director
dhyzak@mainstcapital.com
713-350-6000

Dennard Rupp Gray & Lascar, LLC
Ken Dennard  |  ksdennard@drg-l.com
Ben Burnham |  bburnham@drg-l.com
713-529-6600


'/>"/>
SOURCE Main Street Capital Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
2. Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010
3. Water Street Healthcare Partners Signs Definitive Agreement to Sell Sierra Scientific Instruments to Given Imaging
4. 4-Star General-Former U.S. Drug Czar Barry McCaffrey Featured At Tacoma Treatment Solutions 5-Year Anniv: Mon. May 24, 11 a.m., 9500 Front Street, Lakewood WA 98499
5. Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC
6. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
7. ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
8. Water Street Healthcare Partners Acquires OraPharma, Inc.
9. TPI 2010 Shareholder Annual Meeting on 3/21/11 to Be Held at 100 Wall Street, near NYSE
10. Water Street Healthcare Partners Acquires MarketLab, Inc.
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017 Summary ... to 2022", provides key market data on the North ... millions of US dollars, volume (in units) and average ... Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). The report ... each of these market segements, and global corporate-level profiles ...
(Date:1/16/2017)...  Verathon ® Inc., a leading manufacturer and marketer of ... ® Spectrum TM Single-Use video laryngoscopes. The ... Ambient Light Reduction TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) ...
(Date:1/16/2017)... -- When synthetic Fentanyl arrived on the streets in 2015, ... offered free samples, inviting would-be customers to test a newly-created ... The rapidly-growing demand for ... than morphine, has racked up a staggering death toll across ... dealer,s recorded fentanyl sales reveals that they have sold nearly ...
Breaking Medicine Technology:
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... San ... of iTero Element, the latest in 3-D scanning device which is capable of taking ... the latest advances in dentistry, such as CAD CAM restorations , in terms ...
(Date:1/15/2017)... ... 2017 , ... In this role, Courtney will be responsible for developing new ... allergy friendly mark. This certification program was created by ASL and the nonprofit Asthma ... more suitable for the 60+ million people living in the U.S. with asthma and ...
(Date:1/15/2017)... , ... January 15, 2017 , ... ... Albertsons Companies has achieved accreditation for its specialty care services. Albertsons Companies ... own in-house specialty care service for pharmacy patients. , Accreditation by ACHC reflects ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go this Valentine's Day? ... your door for a romantic, lobster feast in the comfort of your own home. ... The dinners will be featured until February 15th, 2017. , Romantic Dinner one ...
(Date:1/14/2017)... ... January 14, 2017 , ... ... their expanding line of activated charcoal products. With more and more people opting ... their products according to how they cater to specific needs. , Moody Zook ...
Breaking Medicine News(10 mins):